STERIS plc is a leading provider of infection prevention and procedural products and services, operating primarily through three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment, which accounts for the majority of revenue (approximately 70%), supplies hospitals and surgical centers with capital equipment like sterilizers, surgical tables, and lights, alongside equipment maintenance and sterile processing services. The AST segment (approximately 19% of revenue) provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a global network of facilities. The Life Sciences segment (approximately 11% of revenue) designs and manufactures consumable products, such as pharmaceutical detergents and cleanroom disinfectants, as well as specialized sterilizers for research and biopharma production. In fiscal 2025, STERIS divested its Dental segment to focus entirely on its core medical and life sciences markets. The company's business model blends capital equipment sales with recurring revenue from consumables, maintenance, and outsourced sterilization services, positioning it as an essential infrastructure provider for the global healthcare system.
